Hugues Bienaymé
Directeur Général chez ORPHELIA Pharma SAS
Profil
Hugues Bienaymé is the founder of two companies.
He founded Urogene SA in 1998 and ORPHELIA Pharma SAS in 2007, where he held the title of Managing Director and CEO, Director & Chief Scientific Officer respectively.
Dr. Bienaymé also worked as Gérant at Chrysalon SA from 2001 to 2003 and as Principal at Rhône-Poulenc, Inc.
Postes actifs de Hugues Bienaymé
| Sociétés | Poste | Début |
|---|---|---|
ORPHELIA Pharma SAS
 ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | Directeur Général | 01/01/2007 |
Anciens postes connus de Hugues Bienaymé
| Sociétés | Poste | Fin |
|---|---|---|
Urogene SA
 Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Fondateur | 17/10/2012 |
| Rhône-Poulenc, Inc. | Corporate Officer/Principal | - |
Chrysalon SA
 Chrysalon SA Miscellaneous Commercial ServicesCommercial Services Chrysalon SA is a French company that researches and develops medicinal chemical products and pharmaceuticals. The company is based in Villeurbanne, France. Chrysalon was acquired by Urogene SA on March 31, 2002. | Corporate Officer/Principal | 01/01/2003 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Urogene SA
Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | Commercial Services |
Chrysalon SA
Chrysalon SA Miscellaneous Commercial ServicesCommercial Services Chrysalon SA is a French company that researches and develops medicinal chemical products and pharmaceuticals. The company is based in Villeurbanne, France. Chrysalon was acquired by Urogene SA on March 31, 2002. | Commercial Services |
| Rhône-Poulenc, Inc. | Process Industries |
ORPHELIA Pharma SAS
ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | Health Technology |
